The "Anti-Infective Drugs Global Market Report 2019" report has been added to ResearchAndMarkets.com's offering.
Global Anti-Infective Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global anti-infective drugs market.
Where is the largest and fastest growing market for the anti-infective drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Anti-Infective Drugs market global report answers all these questions and many more.
The anti-infective drugs market consists of sales of anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that produce anti-infective drugs to treat microbial infections. This industry includes establishments that produce antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti- helminthic drugs to kill internal parasites and antiprotozoal agents.
North America was the largest region in the global anti-infective drugs market, accounting for 44% of the market in 2018. Western Europe was the second largest region accounting for 23% of the global anti-infective drugs market. Africa was the smallest region in the global anti-infective drugs market.
Companies in this market are active with multiple strategic collaborations and agreements. Top companies in the anti-infective drug market are strategically partnering and collaborating with other companies to broaden their products and services. For instance, in May 2015, Janssen Pharmaceuticals Inc., subsidiary of Johnson & Johnson has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals Inc. to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422 and sovaprevir.
Also in December 2017, Evotec AG was in a strategic alliance with Forge Therapeutics Inc. to advance its novel Gram-negative antibiotic programme targeting 'LpxC' for the treatment of bacterial infections.
Chimerix and ContraVir Pharmaceuticals also entered into a strategic collaboration for antiviral drug candidate CMX157
Key Topics Covered:
1. Executive Summary
2. Report Structure
3. Anti-Infective Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Anti-Infective Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Anti-Infective Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Anti-Infective Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Anti-Infective Drugs Market Trends And Strategies
8. Anti-Infective Drugs Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, Value ($ Billion)
8.2.1. Drivers Of The Market
8.2.2. Restraints On The Market
8.3. Forecast Market Growth, Value ($ Billion)
8.3.1. Drivers Of The Market
8.3.2. Restraints On The Market
9. Anti-Infective Drugs Market Regional Analysis
9.1. Global Anti-Infective Drugs Market, 2018, By Region, Value ($ Billion)
9.2. Global Anti-Infective Drugs Market, 2014 - 2022, Historic And Forecast, By Region
9.3. Global Anti-Infective Drugs Market, Growth And Market Share Comparison, By Region
10. Anti-Infective Drugs Market Segmentation
10.1. Global Anti-Infective Drugs Market, Segmentation By Type, 2014 - 2022, Value ($ Billion)
10.1.1. Antibiotics
10.1.2. Antivirals
10.1.3. Antifungals
10.1.4. Others (Anthelminthic, Antiprotozoal)
11. Anti-Infective Drugs Market Metrics
11.1. Anti-Infective Drugs Market Size, Percentage Of GDP, 2014 - 2022, Global
11.2. Per Capita Average Anti-Infective Drugs Market Expenditure, 2014 - 2022, Global
Companies Mentioned
- Gilead
- Merck & Co
- GlaxosmithKline
- Bristol-Myers Squibb Company
- Johnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/r/snmxul
View source version on businesswire.com: https://www.businesswire.com/news/home/20190725005763/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.